# Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

> **NCT01004978** · PHASE3 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 235 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Unresectable Hepatocellular Carcinoma

## Interventions

- **DRUG:** Cisplatin
- **PROCEDURE:** Computed Tomography
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Doxorubicin-Eluting Beads
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Magnetic Resonance Imaging
- **DRUG:** Mitomycin
- **OTHER:** Pharmacological Study
- **OTHER:** Placebo Administration
- **DRUG:** Sorafenib Tosylate

## Key facts

- **NCT ID:** NCT01004978
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-28
- **Primary completion:** 2021-02-11
- **Final completion:** 2022-12-21
- **Target enrollment:** 235 (ACTUAL)
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004978, "Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01004978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*